Bonnie Gillis

Articles

Sequencing Chemo After Radium-223 Safe in mCRPC

October 26th 2015

Determining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.

Accelerated Partial Breast Irradiation Demonstrates Efficacy in Low-Risk Breast Cancer

October 25th 2015

Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.

Renal Cell Carcinoma Vaccine Fails to Improve Outcomes

October 15th 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC

September 30th 2015

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naÃ¯ve metastatic castration-resistant prostate cancer.

IDH2 Inhibitor Shows Promise in AML

July 18th 2014

An early study presented at the 2014 AACR Annual Meeting showed promise for a new targeted therapy for acute myeloid leukemia

Dacomitinib Shows Promise in Head and Neck Cancer

July 7th 2014

Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

Novel Epigenetic Therapy Shows Clinical Activity in Hematologic Malignancies

July 2nd 2014

Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.

Blood Test Predicts Resistance to Enzalutamide in mCRPC

June 23rd 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

Anti-CD20 Antibodies Continue to Improve Outlook in CLL

January 16th 2014

The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Treatment Advances Bring New Hope in Gastric Cancer

January 7th 2014

Several new drugs have recently shown promise for the treatment of gastric cancer, including rilotumumab, ramucirumab, and anti-HER2 agents, according to a presentation at the 2013 Chemotherapy Foundation Symposium.

CTCs Prognostic But Not Helpful In Switching Therapy in MBC

December 13th 2013

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer

December 13th 2013

PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.

Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors

December 13th 2013

A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.

Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk

December 13th 2013

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

December 12th 2013

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery

December 12th 2013

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

New Approaches Explored in Relapsed/Refractory Multiple Myeloma

October 31st 2013

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Unique Considerations With TKIs for Chronic Myelogenous Leukemia

October 25th 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Dovitinib Fails as Third-Line Option in Kidney Cancer

October 3rd 2013

Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma